POST SUMMARY: The FDA’s plan to test fair balance recall with repeated exposure to TV ads is a further indication that the FDA is out of touch with how consumers are making healthcare treatment decisions. Continue reading →

The Los Angeles Times  says that the FDA is studying whether limiting TV drug ad disclosure only to serious side effects would improve consumer understanding.  “Our hypothesis is that, relative to inclusion of the full major statement, providing limited risk information along with the disclosure about additional risks will promote improved consumer perception and understanding of serious and actionable drug risks,” the FDA said. Ha? Continue reading →